It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Treatment with β-lactam antibiotics, particularly cephalosporins, is a major risk factor for Clostridioides difficile infection. These broad-spectrum antibiotics irreversibly inhibit penicillin-binding proteins (PBPs), which are serine-based enzymes that assemble the bacterial cell wall. However, C. difficile has four different PBPs (PBP1-3 and SpoVD) with various roles in growth and spore formation, and their specific links to β-lactam resistance in this pathogen are underexplored. Here, we show that PBP2 (known to be essential for vegetative growth) is the primary bactericidal target for β-lactams in C. difficile. PBP2 is insensitive to cephalosporin inhibition, and this appears to be the main basis for cephalosporin resistance in this organism. We determine crystal structures of C. difficile PBP2, alone and in complex with β-lactams, revealing unique features including ligand-induced conformational changes and an active site Zn2+-binding motif that influences β-lactam binding and protein stability. The Zn2+-binding motif is also present in C. difficile PBP3 and SpoVD (which are known to be essential for sporulation), as well as in other bacterial taxa including species living in extreme environments and the human gut. We speculate that this thiol-containing motif and its cognate Zn2+ might function as a redox sensor to regulate cell wall synthesis for survival in adverse or anaerobic environments.
Antibiotics of the β-lactam class inhibit bacterial cell wall synthesis by targeting penicillin-binding proteins (PBPs). Here, Sacco et al. study the four PBPs present in the pathogen C. difficile, revealing unique structural features and shedding light on the mechanisms underlying β-lactam resistance in this organism.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 University of South Florida, Department of Molecular Medicine, Morsani College of Medicine, Tampa, USA (GRID:grid.170693.a) (ISNI:0000 0001 2353 285X)
2 University of South Florida, Department of Global and Planetary Health, USF Genomics Program, Global Health and Infectious Disease Center, College of Public Health, Tampa, USA (GRID:grid.170693.a) (ISNI:0000 0001 2353 285X)
3 University of South Florida, Department of Chemistry, Tampa, USA (GRID:grid.170693.a) (ISNI:0000 0001 2353 285X)
4 University of South Florida, School of Geosciences, Tampa, USA (GRID:grid.170693.a) (ISNI:0000 0001 2353 285X)
5 The University of Arizona, Department of Chemistry and Biochemistry, Tucson, USA (GRID:grid.134563.6) (ISNI:0000 0001 2168 186X)
6 University of South Florida, Department of Cell Biology, Microbiology, and Molecular Biology, Tampa, USA (GRID:grid.170693.a) (ISNI:0000 0001 2353 285X)
7 Rutgers, the State University of New Jersey, Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Piscataway, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796)